Cancer Medicines Forum: March 2023

Table of contents

Date: 07/03/2023
Location: Online

Event summary

The 4th Cancer Medicines Forum took place on the 7th March 2023 and reviewed the learnings from the CMF so far on the occasion of its first anniversary.

In addition, discussion on the current HTA experience with real-world data were discussed based on a recent publication co-authored by IQWiG. The use of external control arms for single-arm trials presents challenges for HTA agencies, since it means that these agencies often cannot properly evaluate how the effectiveness of new therapies compares to that of the standard of care. A presentation was given on the activities of the Optimal Cancer Care Alliance (OCCA) which aims to reduce the costs and the toxicity associated with cancer drugs by promoting the conduct of de-escalation trials.

The CMF aims to explore how EMA can contribute towards addressing remaining uncertainties about the use of cancer medicines in clinical practice.

The forum brings together representatives of academic organisations from EMA’s Healthcare Professionals Working Party and the European medicines regulatory network.

The results of discussions will support the prioritisation of actions to fight cancer in EMA's Regulatory Science Strategy to 2025 and Academia Collaboration Matrix Action Plan.

The meetings of the forum are by invitation only.

How useful was this page?

Add your rating
3 ratings